Blood Coagulation Factor Viii, Ahf Patents (Class 530/383)
  • Publication number: 20090271163
    Abstract: The present invention provides crystals of human Factor VIII, in particular, a B-domain deleted human Factor VIII, and its three-dimensional structure. The present invention also provides the structural information of Factor VIII, and methods for identifying compounds that modulate Factor VIII activity, for determining structures of Factor VIII homologs or analogs, and for designing drug candidates for the treatment of hemophilia based on the structural information.
    Type: Application
    Filed: December 5, 2008
    Publication date: October 29, 2009
    Applicant: Wyeth
    Inventors: Jacky Ngo, Mingdong Huang, David A. Roth, Barbara C. Furie, Bruce Furie
  • Publication number: 20090258834
    Abstract: The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to ?1 proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor.
    Type: Application
    Filed: May 24, 2007
    Publication date: October 15, 2009
    Applicant: The American National Red Cross
    Inventors: David J. Hammond, Julia Tait Lathrop, Annemarie Ralston, Timothy K. Hayes, Iwona Fijalkowska
  • Patent number: 7576181
    Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: August 18, 2009
    Assignees: IPSEN Biopharm Limited, Emory University
    Inventors: John S. Lollar, Garrett E. Bergman
  • Publication number: 20090202585
    Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.
    Type: Application
    Filed: March 2, 2009
    Publication date: August 13, 2009
    Inventor: David I. Cohen
  • Patent number: 7560107
    Abstract: Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: July 14, 2009
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 7557188
    Abstract: Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: July 7, 2009
    Assignee: Baxter Innovations GmbH
    Inventors: Hans-Peter Schwarz, Katalin Varadi, Peter Turecek, Hendrik Coenraad Hemker, Suzette Lucette Beguin
  • Publication number: 20090118184
    Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 7, 2009
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Publication number: 20090118185
    Abstract: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 7, 2009
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Patent number: 7521210
    Abstract: The invention provides a method for large-scale production of a polypeptide, such as a Factor VII or Factor VIIa polypeptide, in eukaryote cells, such as mammalian cells, contained in a culture liquid, said method comprising: monitoring the concentration of dissolved CO2 in the culture liquid, and constantly or intermittently sparging atmospheric air through the culture liquid, wherein the sparging rate of the air is controlled in relation to the monitored concentration of dissolved CO2 in the culture liquid. The method reduces or eliminates the use of bases while providing an excellent pH control. The invention also provides a culture vessel suitable for the methods.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: April 21, 2009
    Assignee: Novo Nordisk Healthcare A/G
    Inventor: Ida Mølgaard Knudsen
  • Publication number: 20090099338
    Abstract: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action, for example, baculovirus P35. Further, the animal cell is cultured by a culturing method under a condition that apoptosis is not induced, so that a protein is mass-produced.
    Type: Application
    Filed: October 21, 2004
    Publication date: April 16, 2009
    Applicant: JURIDICAL FOUNDATION THE CHEMO-THERAPEUTIC RESEARC
    Inventors: Reiko Matsuyama, Hiroaki Maeda, Hitomi Shirahama, Takayuki Imamura, Yasuharu Kamachi
  • Publication number: 20090088370
    Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
    Type: Application
    Filed: March 29, 2006
    Publication date: April 2, 2009
    Applicant: Octapharma AG
    Inventor: Stefan Winge
  • Patent number: 7507540
    Abstract: A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: March 24, 2009
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Bayer Pharma
    Inventors: Srinivas Kaveri, SĂ©bastien Lacroix-Desmazes, Michel Kazatchkine
  • Publication number: 20090076237
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: August 1, 2008
    Publication date: March 19, 2009
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann
  • Patent number: 7501493
    Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: March 10, 2009
    Assignee: Quadrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Publication number: 20090047251
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Application
    Filed: September 8, 2006
    Publication date: February 19, 2009
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Publication number: 20090041714
    Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
    Type: Application
    Filed: June 6, 2008
    Publication date: February 12, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventors: Mary J. Bossard, Michael D. Bentley, Ping Zhang
  • Publication number: 20090042784
    Abstract: The present invention relates to a purification process for drug substances of a Factor VII polypeptide having an impurity in the form of desGla-Factor VII polypeptide structures. The process utilizes an anion-exchange material and includes washing and/or elution with a buffer of a predetermined pH.
    Type: Application
    Filed: September 29, 2005
    Publication date: February 12, 2009
    Inventor: Janus Krarup
  • Publication number: 20090011992
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 21, 2006
    Publication date: January 8, 2009
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Ole Hvilsted Olsen, Jais Rose Bjelke, Egon Persson
  • Publication number: 20080312143
    Abstract: The present invention relates to modified DNA sequences coding for biologically active recombinant human factor VIII and its derivatives, recombinant expression vectors containing such DNA sequences, host cells transformed with such recombinant expression vectors, and processes for the manufacture of the recombinant human factor VIII and its derivatives. The invention also covers a transfer vector for use in human gene therapy which comprises such modified DNA sequences. The present invention relates to modified DNA sequences coding for biologically active recombinant human factor VIII and its derivatives, recombinant expression vectors containing such DNA sequences, host cells transformed with such recombinant expression vectors, and processes for the manufacture of the recombinant human factor VIII and its derivatives. The invention also covers a transfer vector for use in human gene therapy which comprises such modified DNA sequences.
    Type: Application
    Filed: October 13, 2004
    Publication date: December 18, 2008
    Applicant: ZLB BEHRING GMBH
    Inventors: Hans-Peter Hauser, Jean-Luc Plantier, Cecille Ducasse, Claude Negrier
  • Publication number: 20080300174
    Abstract: FVIII heavy chain mutants are provided which exhibit enhanced secretion from transfected cells and robust anti-coagulation activity.
    Type: Application
    Filed: October 11, 2007
    Publication date: December 4, 2008
    Inventor: Weidong Xiao
  • Publication number: 20080281081
    Abstract: Blood collection, processing and transfer leads to the separation of discrete fractions by adding additional citrate (trisodium citrate) to bring the citrate concentration to 10%-15% w/v thereby leading to enhanced yield and purity of cryoprecipitate. The improved cryoprecipitate then yields concentrated clotting factors by an improved extraction process which uses polyvinyl pyrollidone to reduce the extraction of fibrinogen.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 13, 2008
    Applicant: SHANBROM TECHNOLOGIES, LLC
    Inventor: Edward SHANBROM
  • Publication number: 20080280818
    Abstract: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.
    Type: Application
    Filed: July 23, 2007
    Publication date: November 13, 2008
    Applicant: Neose Technologies, Inc.
    Inventor: Shawn DeFrees
  • Publication number: 20080227691
    Abstract: The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.
    Type: Application
    Filed: April 3, 2006
    Publication date: September 18, 2008
    Applicant: Novo Nordisk Health Care AG
    Inventors: Henrik Ostergaard, Gert Bolt, Thomas Dock Steenstrup
  • Publication number: 20080227205
    Abstract: The invention provides methods and compositions for in vivo incorporation of non-naturally encoded amino acids into polypeptides by Pseudomonas species and strains derived therefrom. Also provided are compositions including proteins with non-naturally encoded amino acids made by Pseudomonas species and strains derived therefrom.
    Type: Application
    Filed: June 2, 2006
    Publication date: September 18, 2008
    Applicant: AMBRX, INC.
    Inventor: Ho Sung Cho
  • Publication number: 20080200651
    Abstract: The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.
    Type: Application
    Filed: June 19, 2006
    Publication date: August 21, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Henrik Ostergaard, Anders Klarskov Petersen
  • Publication number: 20080146782
    Abstract: The present invention provides conjugates between peptides and PEG moieties through glycerol linkers.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 19, 2008
    Applicant: Neose Technologies, Inc.
    Inventors: Shawn DeFrees, Xiao Nong Zeng
  • Patent number: 7381796
    Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: June 3, 2008
    Assignee: Quadrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Publication number: 20080113412
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Applicant: AMBRX, INC.
    Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
  • Publication number: 20080113411
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Applicant: AMBRX, INC.
    Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
  • Publication number: 20080064855
    Abstract: The present invention relates generally to a modified hemoglobin with an allosteric effector conjugated which is capable of dynamically regulating the efficiency of oxygen release. The hemoglobin composition provided in the present invention is utilizing maleimide-Polyethylene glycol-N-hydroxysuccinimidyl as a linker to crossbridge the peptide comprising SEQ ID NO: 1 to the surface of a hemoglobin, and hence, it would able to modulate the oxygen affinity through the characteristic of the peptide which could enter into the central cavity formed between ?- chains of hemoglobin under an appropriate oxygen concentration.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 13, 2008
    Inventors: Kuang-Tse Huang, Yen-Lin Lin
  • Patent number: 7323442
    Abstract: The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: January 29, 2008
    Assignee: Meiji Dairies Corporation
    Inventors: Masako Yajima, Makiko Nakayama, Yumi Tsukamoto, Kaoru Koide, Tamotsu Kuwata, Takaji Yajima
  • Patent number: 7300922
    Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: November 27, 2007
    Assignee: Duke University
    Inventors: Bruce A. Sullenger, Christopher P Rusconi
  • Publication number: 20070197440
    Abstract: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.
    Type: Application
    Filed: February 8, 2007
    Publication date: August 23, 2007
    Applicant: GRIFOLS, S.A.
    Inventors: Salvador Grancha Gamon, Pere Ristol Debart, Juan Ignacio Jorquera Nieto
  • Patent number: 7253262
    Abstract: A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: August 7, 2007
    Assignee: Quandrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Patent number: 7247707
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: July 24, 2007
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 7244825
    Abstract: A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: July 17, 2007
    Assignee: Quadrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Patent number: 7244824
    Abstract: A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: July 17, 2007
    Assignee: Quadrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Patent number: 7220836
    Abstract: A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: May 22, 2007
    Assignee: Quadrant Drug Delivery Limited
    Inventor: Bruce Joseph Roser
  • Patent number: 7211559
    Abstract: The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: May 1, 2007
    Assignee: University of Maryland, Baltimore
    Inventors: Evgueni L. Saenko, Andrey G. Sarafanov, Natalya M. Ananyeva
  • Patent number: 7211558
    Abstract: Improved materials and methods for the treatment of Hemophilia A are provided.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: May 1, 2007
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Katherine A. High, Rodney M. Camire
  • Patent number: 7205278
    Abstract: The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: April 17, 2007
    Assignee: The Scripps Research Institute
    Inventors: John H. Griffin, Andrew J. Gale, Elizabeth D. Getzoff, Jean-Luc Pellequer
  • Patent number: 7199223
    Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: April 3, 2007
    Assignee: Nektar Therapeutics AL, Corporation
    Inventors: Mary J. Bossard, Michael D. Bentley
  • Patent number: 7166709
    Abstract: A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, followed by purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation; and heating the preparation for inactivating viruses.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: January 23, 2007
    Assignee: Octapharma AG
    Inventors: Djuro Josic, Monika Stadler, Gerhard Gruber
  • Patent number: 7122634
    Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: October 17, 2006
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 7087723
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 8, 2006
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 7041635
    Abstract: The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: May 9, 2006
    Assignee: IN2GEN Co., Ltd.
    Inventors: Hun-Taek Kim, In-Young Song, Jae Won Choi, Jin-Wook Jang, Yong-Kook Kim, Ho Soon Lee, Yung-Jue Bang, Dae-Kee Kim
  • Patent number: 7015193
    Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: March 21, 2006
    Assignee: University of Vermont
    Inventors: Saulius Butenas, Kenneth G. Mann, Kathleen Brummel
  • Patent number: 7012132
    Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: March 14, 2006
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 7005502
    Abstract: Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: February 28, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Hans-Peter Schwarz, Katalin Varadi, Peter Turecek, Hendrik Coenraad Hemker, Suzette Lucette Beguin
  • Patent number: RE39321
    Abstract: This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 3, 2006
    Assignee: The American National Red Cross
    Inventors: Martin J. MacPhee, William N. Drohan, Gene Liau, Hernan Nunez, Wilson H. Burgess, Jeffrey O. Hollinger, Thomas Maciag